Walking and Dietary Modification for Recurrent Early Miscarriages (W&D)

• ClinicalTrials.gov Identifier: NCT03023137
• Recruitment Status: Completed
• First Posted: January 18, 2017
• Results First Posted: April 6, 2017
• Last Update Posted: April 10, 2017
• Sponsor: Hospital dos Servidores do Estado do Rio de Janeiro
• Information provided by (Responsible Party): Silvia Hoirisch Clapauch, Hospital dos Servidores do Estado do Rio de Janeiro

Study Description

Brief Summary:

This study is part of a big one aiming to evaluate how lifestyle interventions during pregnancy affect obstetric results, neonatal metabolism and the intelligence of the offspring (study not yet completed). Data regarding obstetric and neonatal results were entered in NCT01409382, but we decided to split results in two for the sake of clarity.

A cohort of women with early pregnancy losses without antiphospholipid antibodies was selected for two reasons. One is that these women follow strictly the recommendadtions. The second is that no medication has been shown to increase the rate of take-home babies in women with early miscarriages who test negative for antiphospholipid antibodies. We decided to focus on the fibrinolytic system because trophoblast migration and placental vasculogenesis and angiogenesis depend on plasmin-dependent extracellular matrix remodeling. Plasminogen activator inhibitor (PAI)-1 inhibits the generation of plasmin. Since both glucose and insulin increase PAI-1 synthesis, hyperglycemia itself, or by stimulating insulin production, reduces plasmin generation, which may impair placentation.

Abnormalities in glucose metabolism may be also deleterious to embryos by causing epigenetic changes. Chromosomal abnormalities are considered an important cause of early pregnancy losses.

Several lines of evidence lend support to the hypothesis that carbohydrate metabolism abnormalities contribute to the pathogenesis of recurrent early pregnancy losses. One is that of the pregnancies of the women with polycystic ovary syndrome, around 30 and 50% end with first-trimester miscarriages. Hyperinsulinemia is a prevalent feature of the syndrome, and interventions proven effective in reducing insulin levels, such as metformin, have been shown to reduce the rate of early miscarriages. The other is that patients with body mass index of ≥25 kg/m2 have significantly higher odds of early miscarriage, regardless of the method of conception.

The investigator's hypothesis was that a balanced diet combined to regular exercise, by improving glucose homeostasis, would increase the take-home baby rate in women with consecutive early miscarriages. Moderate exercises are usually well tolerated not only by the mother, but also by the fetus, as indicated by tests of fetal well-being, including umbilical artery systolic to diastolic ratio.

Condition or disease	Intervention/treatment	Phase
Recurrent Miscarriage	Behavioral: Walking & dietary modification	Not Applicable

Detailed Description:

Women aged 18 to 40 years trying to conceive spontaneously were eligible if they had two or more consecutive pregnancy losses in the first trimester, documented by pathology or ultrasound-confirmed gestational sac.

All participants underwent ultrasound examination before inclusion in the study. Exclusion criteria were any of the following: anatomic anomalies that may increase the risk of pregnancy losses, not amenable to surgical correction during pregnancy, such as uterine septum; antiphospholipid antibodies; prior second- or third-trimester losses; current multiple gestation; disabilities such as hemiplegia or paraplegia; renal or liver failure; conditions requiring a priori anticoagulation.

Participants were enrolled by staff at the participating center. Randomization to the intervention protocol Walking and Diet (W&D) or to a control group was performed before pregnancy occurred by a statistician using a computer-generated random-number table. This was not a double blind study, but care was taken to ensure that appointments of the patients assigned to the intervention protocol did not coincide with those of controls.

The intervention was standardized by training of research staff. Women assigned to W&D were instructed to walk at a moderate pace (4 km/h) for at least 40 minutes, seven days a week. Besides, those who remained seated most of the day were advised to walk 25 to 30 minutes twice a day, avoiding hence more than 12 hours of physical inactivity. Walking could be replaced by stationary bicycle rides or swimming when convenient, which often occurred near term and when the mother was obese. Strenuous exercises were discouraged.

Patients assigned to protocol W&D were also informed of the importance of a balanced diet and recommended to avoid high-glycemic index meals (high-carbohydrate, low-fiber). Sucralose could be used as a sweetener. As a strategy to promote satiety and reduce carbohydrate intake, W&D participants were also advised to eat at least two daily servings of protein-rich food. The intervention began when participants wished to conceive, continuing until delivery. Careful instructions about walking speed and diet were given to participants assigned to W&D at enrolment and at each consultation. During exercise, neither fetal nor maternal cardiac rate were assessed.

Non-adherence to the intervention protocol was suspected when non-obese participants assigned to W&D gained > 1 kg in 4 weeks until the 28th week of gestation, > 1.5 kg from the 28th to the 32nd week, and > 2 kg in 4 weeks thereafter, in the absence of edema. The threshold was lower for obese participants: > 700 g in 4 weeks until the 28th week of gestation, > 1 kg from the 28th to the 32nd week, and > 1.5 kg in 4 weeks thereafter21. Excessive weight gain aroused the suspicion of protocol violation because high carbohydrate consumption, especially when combined with physical inactivity stimulates the pancreas to overproduce insulin, a hormone that promotes fat storage. To enhance adherence to the protocol, W&D participants who gained excessive weight were recommended to increase the frequency, duration and intensity of the physical activity and to increase the protein intake. Participants of the W&D group who had a successful pregnancy volunteered to encourage mothers assigned to the intervention protocol, especially those who gained excessive weight.

At enrollment and during first-trimester consultations, W&D participants were explained that antiemetics such as ondansetron should be taken before nausea became severe, in order to help them tolerate balanced meals.

No recommendations regarding diet or physical activity were given to controls. Antiemetics such as ondansetron were given to controls who complained of hyperemesis.

All participants were given folic acid tablets 5 mg daily until 14 weeks of gestation, as prevention of neural tube defects. In both groups, participants reporting abdominal pain, cramps, and vaginal bleeding during the first-trimester were medicated with vaginal progesterone. Subcutaneous heparin was given to all participants whose pregnancies were complicated with nephrotic range proteinuria or any evidence of placental insufficiency. Antihypertensive medications included methyldopa, amlodipine and hydralazine. No patient received aspirin or metformin in this study.

Appointments were scheduled according to the routine. Maternal weight and blood pressure were assessed at every appointment and all mothers were screened for gestational diabetes according to the American Diabetes Association recommendations.

Obstetric and neonatal outcomes were obtained from the hospital records. Neonates were classified as small, appropriate or large for gestational age according to Olsen et al. growth curves.

Written informed consent was obtained from each participant after a full explanation of the study.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 480 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Outcomes Assessor)
• Masking Description: Participants were not blinded, but visits of the two groups were scheduled so as to not coincide..
• Primary Purpose: Prevention
• Official Title: Walking and Dietary Modification for Women With Consecutive Early Miscarriages: a Randomized Study
• Study Start Date: May 2011
• Actual Primary Completion Date: August 2016
• Actual Study Completion Date: February 2017

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Walking & dietary modification (W&D); W&D should begin when participants wish to conceive. The intervention was standardized by training of research staff. Careful instructions about walking speed and diet would be given to participants assigned to W&D at enrolment and at each consultation.	Behavioral: Walking & dietary modification; Daily walking at a moderate pace (4 km/h) > 40 min, 7/7. Those remaining seated most of the day should walk 25-30 min twice a day, avoiding >12 h of physical inactivity. Walking may be replaced by stationary bicycle rides or swimming when convenient, which often occurred near term and when the mother was obese.; At least two daily servings of protein-rich food (≥ 4 g/kg of meat, poultry, fish or eggs) per day. Avoidance of high-carbohydrate, low-fiber meals, such as snacks, candies, fiber-free juices, coconut water or sugar-sweetened beverages. Sucralose could be used as a sweetener. Participants are recommended to use ondansetron for nausea and vomiting prevention; Other Name: W&D
No Intervention: Controls; No recommendations regarding diet or physical activity were given to controls. Antiemetics such as ondansetron would be given to controls complaining of vomiting.

Outcome Measures

Primary Outcome Measures :

1. Take-home Baby Rate [ Time Frame: End of pregnancy ]

Secondary Outcome Measures :

1. Gestational Diabetes Mellitus [ Time Frame: Pregnancies reaching 24 weeks' gestation ]
2. Preeclampsia [ Time Frame: Pregnancies reaching 20 weeks' gestation ]
3. Mothers Who Used Heparin for Nephrotic Range Proteinuria or Placental Insufficiency [ Time Frame: End of pregnancy ]
4. Excessive Weight Gain [ Time Frame: End of term pregnancies ]
   Weight gain >13 kg for underweight, normal weight or overweight mothers and > 9 kg for obese mothers
5. First-trimester Losses [ Time Frame: 14 weeks of gestation ]
6. Second and Third-trimester Losses [ Time Frame: 28 weeks of gestation and end of gestation ]
7. Live-born Children [ Time Frame: End of pregnancy ]
8. Babies Born at Term [ Time Frame: End of pregnancy ]
9. Appropriate-for-gestational Age Babies [ Time Frame: End of pregnancy ]
10. Neonates With Hypoglycemia [ Time Frame: One, two and fours hours after birth ]
    Hypoglycemia was defined as any blood glucose concentration ≤ 40 mg/dL.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 40 Years (Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• ≥ 2 consecutive pregnancy losses in the first trimester;
• losses should be documented by pathology or ultrasound-confirmed gestational sac.

Exclusion Criteria (any of the following):

• anatomic anomalies that may increase the risk of pregnancy losses, not amenable to surgical correction during pregnancy, such as uterine septum;
• antiphospholipid antibodies;
• prior second- or third-trimester losses;
• current multiple gestation;
• disabilities such as hemiplegia or paraplegia;
• renal or liver failure;
• conditions requiring a priori anticoagulation

Contacts and Locations

Locations

Brazil

Hospital Federal dos Servidores do Estado, Ministry of Health

Rio de Janeiro, RJ, Brazil, 20221-903

Sponsors and Collaborators

Hospital dos Servidores do Estado do Rio de Janeiro

Investigators

• Principal Investigator: Silvia Hoirisch-Clapauch, MD, PhD; Hospital Federal dos Servidores do Estado

More Information

• Responsible Party: Silvia Hoirisch Clapauch, Principal Investigator, Hospital dos Servidores do Estado do Rio de Janeiro
• ClinicalTrials.gov Identifier: NCT03023137
• Other Study ID Numbers: HospitalSERJ
• First Posted: January 18, 2017
• Results First Posted: April 6, 2017
• Last Update Posted: April 10, 2017
• Last Verified: April 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Silvia Hoirisch Clapauch, Hospital dos Servidores do Estado do Rio de Janeiro:

prevention; carbohydrate; exercise; neonatal hypoglycemia

Additional relevant MeSH terms:

Abortion, Spontaneous; Abortion, Habitual; Pregnancy Complications